New Analysis of Rekovelle® Data Further Supports Use of AMH to Persona…

기사입력 2018.07.04 17:45
댓글 0
  • 페이스북으로 보내기
  • 트위터로 보내기
  • 구글플러스로 보내기
  • 밴드로 보내기
  • 카카카오스토리로 보내기
  • 기사내용 프린트
  • 기사 스크랩
  • 기사 내용 글자 크게
  • 기사 내용 글자 작게

(Business Wire / Korea Newswire) Ferring Pharmaceuticals announced today a new analysis* of data from the Phase 3 ESTHER-1 trial[1] showing that natural variations in anti-Müllerian hormone (AMH) levels during and between a woman’s menstrual cycle have no clinically relevant impact on ovarian response (the number of eggs produced) when using AMH to dose Rekovelle® (follitropin delta) for ovarian stimulation (OS).[2] The data were presented today at the 34th Annual Meeting of the European Society of Human Reproduction and Embryology (ESHRE) in Barcelona, Spain.


According to the new analysis, for 95% of women treated with Rekovelle, variations in ovarian response were limited to a difference of plus or minus one egg.[2] This reinforces that AMH measured on any day of a woman’s menstrual cycle can be used to individualise the dose of Rekovelle. AMH is measured with a companion diagnostic, the Elecsys® AMH Plus immunoassay from F. Hoffmann-La Roche Ltd (Roche).
“We are excited to share the results of this new Rekovelle analysis which add to existing evidence showing AMH is a robust predictor of ovarian response to fertility treatment,” said Professor Klaus Dugi, Chief Medical Officer, Ferring Pharmaceuticals. “I believe these data will further strengthen the growing confidence of doctors in the use of AMH to personalise dosing of fertility treatment for their patients.”


Ovarian response to stimulation varies considerably from woman to woman[3] and unexpected extreme responses have implications on efficacy and safety.[4,5] Aiming to avoid extremes in ovarian response, the validated Rekovelle dosing algorithm uses AMH and body weight to determine a personalised dose for patients, from the start of treatment.


This analysis of data from the Phase 3 ESTHER-1 trial adds to consistent efficacy results seen with Rekovelle in clinical trials to date. The ESTHER-1 trial showed that women undergoing their first treatment cycle receiving individualised treatment with Rekovelle, compared to conventional dosing regimen with follitropin alfa,Ɨǂ had similar ongoing pregnancy and embryo implantation rates.[1]


The ESTHER-1 trial also showed that more women receiving individualised treatment with Rekovelle achieved the target response of 8-14 eggs compared to conventional dosing regimen with follitropin alfa.1ǂ§ Evidence shows that beyond 15 eggs there is no additional benefit, in terms of live birth rate, in the number of eggs produced through OS in a fresh cycle.[6,7]

3698601005_20180703184556_2855889312[1].jpg

AMH Infographic

 

 

 


About Rekovelle (follitropin delta)
Rekovelle is a human recombinant follicle stimulating hormone (rFSH) with an approved dosing algorithm designed for predictable ovarian response.[8] It is the first rFSH derived from a human cell line (PER.C6® cell line). Rekovelle is structurally and biochemically distinct from other existing rFSH gonadotrophins.[8,9] Rekovelle is approved for use in ovarian stimulation (OS) for induction of the development of multiple follicles in women undergoing assisted reproductive technologies (ART), such as an in vitro fertilisation (IVF) or intracytoplasmic sperm injection (ICSI).[8] The individualised dosing of Rekovelle is determined using an approved algorithm, based on a woman’s anti-Müllerian hormone (AMH) level and body weight.[1,8,10] AMH is a biomarker used to assess ovarian reserve and can help predict ovarian response.[11] AMH will be measured with a companion diagnostic, the Elecsys® AMH Plus immunoassay from F. Hoffmann-La Roche Ltd (Roche).[12,13]
As of 15 June 2018, Rekovelle was approved in 37 countries and available in 17 countries worldwide.


About the ESTHER trials
The ESTHER trials (Evidence-based Stimulation Trial with Human recombinant FSH in Europe and Rest of World) were randomised, assessor-blind, controlled, multicentre Phase 3 trials involving patients in 11 countries and over 2,000 cycles of OS.[1,14]


ESTHER-1 was a trial of 1,326 patients in 11 countries undergoing their first ART cycle. Patients were randomised 1:1 to receive treatment with individualised Rekovelle, a fixed daily dose based on serum AMH levels** and body weight, or conventional follitropin alfa dosing.1ǂ The co-primary endpoints of ongoing pregnancy rates and ongoing implantation rates were met, demonstrating comparable efficacy of Rekovelle to conventional treatment.[1] Rekovelle’s individualised dosing regimen aims to obtain an ovarian response associated with a favourable safety/efficacy profile, i.e. aims to achieve an adequate number of eggs and reduce interventions to prevent ovarian hyperstimulation syndrome.[8]


ESTHER-2 evaluated the immunogenicity of Rekovelle in a subset of ESTHER-1 patients undergoing repeated cycles of OS for ART. Data demonstrated no increased immunogenicity risk with Rekovelle after exposure in repeated cycles.[8,14]

[Choi Ann, Reporter 기자 ann@worldyan.com]
  • 페이스북으로 보내기
  • 트위터로 보내기
  • 구글플러스로 보내기
  • 밴드로 보내기
  • 카카카오스토리로 보내기
<저작권자ⓒ월드얀 & worldyan.com 무단전재-재배포금지>
 
회사소개 | 광고안내 | 제휴·광고문의 | 기사제보 | 다이렉트결제 | 고객센터 | 저작권정책 | 개인정보취급방침 | 청소년보호정책 | 독자권익보호위원회 | 이메일주소무단수집거부 | RSS top
모바일 버전으로 보기